In general, tau-targeting therapies remain challenging because of an incomplete understanding of AD, the lack of robust and sensitive biomarkers for diagnosis and response monitoring, and the obstruction of the blood–brain barrier (BBB) [11]. Here, MAPT is linked to Alzheimer disease.